FF-10502 is a pyrimidine nucleoside antimetabolite and a structural analog of Gemcitabine. This compound effectively inhibits DNA polymerase α and β, demonstrating potent anticancer activity by targeting dormant cells.

FF-10502 (0.1 nM-10 μM; 72 hours) shows the growth inhibition of pancreatic cancer cell lines, with IC 50 s of 59.9 nM, 39.6 nM, 68.2 nM, and 331.4 nM for BxPC-3, SUIT-2, Capan-1, and MIA PaCa-2 cells, respectively[1]. Cell Viability Assay[1]Cell Line: Human pancreatic cancer cell lines (BxPC-3, SUIT-2, Capan-1, and MIA PaCa-2) Concentration: 0.1 nM to 10 μM Incubation Time: 72 hours Result: Inhibited the growth of pancreatic cancer cell lines.

FF-10502 (120-480 mg/kg; i.v; once weekly; for 4 weeks) shows an antitumor effect in a mouse xenograft model with the subcutaneously implanted human pancreatic cancer cell line Capan-1[1]. Animal Model: Five-week-old female nude mice (BALB/c-nu/nu) injected with Capan-1 cells[1]. Dosage: 120 mg/kg, 240 mg/kg, 360 mg/kg, and 480 mg/kg Administration: Tail vein injection; once weekly; for 4 weeks Result: Suppressed tumor growth in a dose-dependent manner in mice.